武田获得rusfertide治疗veria的批准

2026-08-29 05:44

The US FDA approved Takeda Pharmaceutical's (TAK) Mimrylo (rusfertide), a first-in-class treatment for the rare blood disorder polycythemia vera.
Mimrylo works by mimicking hepcidin, a hormone that naturally regulates iron. The drug limits the iron in the body to make new red blood cells, cutting their their overproduction and mainiaining healthy red blood cell levels.
Approval was based on data from the VERIFY placebo-controlled trial of about 300 adults with PV over 32 weeks. Results showed that 76.9% of patients on Mimrylo didn't need any phlebotomies vs. 32.9% on placebo.
Mimrylo was granted priority review.

More on Takeda Pharmaceutical